CompletedNot Applicable

The Effect of Slow-Paced Breathing on Patient Outcomes in Pulmonary Arterial Hypertension

Turkey (Türkiye)42 participantsStarted 2023-06-11

Plain-language summary

This study aims to investigate the effects of slow-paced breathing (SPB) intervention applied to patients with pulmonary arterial hypertension (PAH) in the home environment on symptom management (dyspnea, fatigue, sleep quality), clinical parameters (Six-Minute Walking Test-6MWT), IL-6, NT-proBNP results) and quality of life.

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Being between 18 and 65 years of age * Being diagnosed with PAH (pulmonary arterial hypertension)- (Group I pulmonary hypertension (idiopathic, hereditary, drug or toxin-induced, or associated with connective tissue disease, congenital heart disease, or HIV-associated)) diagnosed by right heart catheterization * Being on stable PAH treatment for the past three months and in a stable clinical condition (no changes in PAH medical treatment, no new medications added) * Being in class II or III according to the World Health Organization functional classification * Being able to speak Turkish * Having a high level of technical digital literacy (obtaining the highest score (30 points) on the "technical subscale" of the Digital Literacy Scale\*) * Agreeing to participate in the study Exclusion Criteria: * Communication difficulties * Symptomatic hypotension * Pregnancy status for female participants (positive urine pregnancy test\*) * Presence of another underlying condition that may cause dyspnea, fatigue, and sleep difficulties (chronic fatigue syndrome, obstructive sleep apnea, restless legs syndrome, narcolepsy, major depression, etc.) * Hospitalization or acute phase * Active participation in a cardiac rehabilitation program * Presence of pulmonary hypertension due to left heart disease and pulmonary hypertension due to lung diseases and/or hypoxia * Receiving a lung transplant * Having had cardiac surgery within the last six months * Presence of obesit…

What they're measuring

Multidimensional Dyspnea Profile

Timeframe: Baseline, at the end of six weeks and at the end of twelve weeks

Multidimensional Fatigue Inventory

Timeframe: Baseline, at the end of six weeks and at the end of twelve weeks

Pittsburgh Sleep Quality Index

Timeframe: Baseline, at the end of six weeks and at the end of twelve weeks

Six-Minute Walk Test Form and Modified Borg Scale

Timeframe: Baseline, and at the end of twelve weeks

Laboratory Analysis Form

Timeframe: Baseline, and at the end of twelve weeks

EmPHasis-10 Quality of Life Scale

Timeframe: Baseline, at the end of six weeks and at the end of twelve weeks

Trial details

NCT IDNCT07232368

SponsorEge University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-09-15

View on ClinicalTrials.gov More Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) trials

Plain-language summary

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Multidimensional Dyspnea Profile

Timeframe: Baseline, at the end of six weeks and at the end of twelve weeks

Multidimensional Fatigue Inventory

Timeframe: Baseline, at the end of six weeks and at the end of twelve weeks

Pittsburgh Sleep Quality Index

Timeframe: Baseline, at the end of six weeks and at the end of twelve weeks

Six-Minute Walk Test Form and Modified Borg Scale

Timeframe: Baseline, and at the end of twelve weeks

Laboratory Analysis Form

Timeframe: Baseline, and at the end of twelve weeks

EmPHasis-10 Quality of Life Scale

Timeframe: Baseline, at the end of six weeks and at the end of twelve weeks